مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

332
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

185
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

COMPARISON OF A GENERIC AND A BRAND METFORMIN PRODUCTS IN TYPE II DIABETES: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL STUDY

Author(s)

 TABATABAEI MALAZI A. | HESHMAT RAMIN | TAHERI E. | ARDESHIR LARIJANI MOHAMMAD BAGHER | Issue Writer Certificate 

Pages

  113-117

Abstract

 Metformin is often prescribed for glycemic control in type II diabetes mellitus. This drug is the first line treatment for obese without renal or liver failure. Different pharmaceutical types of METFORMIN are available. As a CLINICAL TRIAL, THERAPEUTIC EFFECTS of a generic (Aria Pharmaceutical Company, Iran) with a brand METFORMIN (Glucophage, product of Merck pharmaceutical company, France) in diabetic patients were compared. This double blind randomized CLINICAL TRIAL study was performed in 60 non-pregnant diabetic patients in order to compare THERAPEUTIC EFFECTS of combination therapy (Glibenclamide - METFORMIN "Generic or Brand" a 12-week period). Patients were evaluated for FBS, BS2hpp, HbA1C, lipid profile, liver function tests, weight, BMI, and side effects. Both pharmaceutical types of METFORMIN had the same THERAPEUTIC EFFECTS for controlling of glycemia, and lipid profile and weight, between two groups statistically were not significantly different. GI discomfort (distention) was the most common side effects of both drugs (33%). There were no significant statistical differences between these two products regarding their side effects and 70% of patients were satisfied by taking each kind of product. On the basis of results, while both products had comparable efficacy, the generic product which is a domestic product and easier for patients to have access to it showed fewer side effects.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    TABATABAEI MALAZI, A., HESHMAT, RAMIN, TAHERI, E., & ARDESHIR LARIJANI, MOHAMMAD BAGHER. (2007). COMPARISON OF A GENERIC AND A BRAND METFORMIN PRODUCTS IN TYPE II DIABETES: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL STUDY. DARU JOURNAL OF PHARMACEUTICAL SCIENCE, 15(2), 113-117. SID. https://sid.ir/paper/275404/en

    Vancouver: Copy

    TABATABAEI MALAZI A., HESHMAT RAMIN, TAHERI E., ARDESHIR LARIJANI MOHAMMAD BAGHER. COMPARISON OF A GENERIC AND A BRAND METFORMIN PRODUCTS IN TYPE II DIABETES: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL STUDY. DARU JOURNAL OF PHARMACEUTICAL SCIENCE[Internet]. 2007;15(2):113-117. Available from: https://sid.ir/paper/275404/en

    IEEE: Copy

    A. TABATABAEI MALAZI, RAMIN HESHMAT, E. TAHERI, and MOHAMMAD BAGHER ARDESHIR LARIJANI, “COMPARISON OF A GENERIC AND A BRAND METFORMIN PRODUCTS IN TYPE II DIABETES: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL STUDY,” DARU JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 15, no. 2, pp. 113–117, 2007, [Online]. Available: https://sid.ir/paper/275404/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button